Abstract

BackgroundDue to its inflammatory nature, rheumatoid arthritis (RA) is associated with a variety of comorbidities and individual risk factors [1]. The benefit of a nurse-led programme on RA comorbidity management...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
OP0137 Assessing the risk of ra patients for comorbid conditions through a structured nurse-led interview – the eriko study
R Eder ... K Rietzler
Annals of the Rheumatic Diseases | VOL. 77
R Eder, et. al.R Eder ... K Rietzler
01 Jun 2018
OP0293 Implementation of the Eular Recommendations for Cardiovascular Risk Management in Germany: Results of A Cross-Sectional Epidemiologic Study
R Hecker ... U Müller-Ladner
Annals of the Rheumatic Diseases | VOL. 73
R Hecker, et. al.R Hecker ... U Müller-Ladner
01 Jun 2014
AB0437 Adalimumab therapy results in sustained response in rheumatoid arthritis patients over 5 years: the german noninterventional agil study
...
Annals of the Rheumatic Diseases | VOL. 77
, et. al. ...
01 Jun 2018
SAT0358 Impact of Methotrexate on Anti-TNF Treatment in Psoriatic Arthritis? an In-Depth Analysis of A Large Prospective Observational Study with Adalimumab
E Scharbatke ... G Greger
Annals of the Rheumatic Diseases | VOL. 73
E Scharbatke, et. al.E Scharbatke ... G Greger
01 Jun 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers